This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IVERIC bio Future Growth

Future criteria checks 5/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for IVERIC bio.

Key information

59.0%

Earnings growth rate

61.5%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	58.0%
Future return on equity	n/a
Analyst coverage	Good
Last updated	23 Jun 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:O2T - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	365	-28	57	N/A	9
12/31/2024	124	-200	-131	-154	9
12/31/2023	11	-281	-212	-236	8
3/31/2023	N/A	-223	-178	-177	N/A
12/31/2022	N/A	-185	-165	-164	N/A
9/30/2022	N/A	-159	-138	-137	N/A
6/30/2022	N/A	-141	-123	-122	N/A
3/31/2022	N/A	-122	-107	-107	N/A
12/31/2021	N/A	-115	-99	-99	N/A
9/30/2021	N/A	-107	-97	-97	N/A
6/30/2021	N/A	-108	-86	-86	N/A
3/31/2021	N/A	-96	-78	-78	N/A
12/31/2020	N/A	-85	-66	-66	N/A
9/30/2020	N/A	-77	-57	-57	N/A
6/30/2020	N/A	-66	-54	-54	N/A
3/31/2020	N/A	-61	-51	-51	N/A
12/31/2019	N/A	-59	-48	-48	N/A
9/30/2019	N/A	63	-47	-47	N/A
6/30/2019	N/A	62	-45	-45	N/A
3/31/2019	N/A	64	-44	-44	N/A
12/31/2018	N/A	63	-42	-42	N/A
9/30/2018	N/A	-51	-45	-45	N/A
6/30/2018	207	153	-50	-50	N/A
3/31/2018	208	144	-72	-72	N/A
12/31/2017	210	114	-122	-122	N/A
9/30/2017	215	57	-142	-141	N/A
6/30/2017	10	-192	-132	-131	N/A
3/31/2017	37	-200	-134	-133	N/A
12/31/2016	51	-193	N/A	-109	N/A
9/30/2016	50	-163	N/A	-115	N/A
6/30/2016	52	-141	N/A	-133	N/A
3/31/2016	26	-149	N/A	-84	N/A
12/31/2015	52	-106	N/A	-79	N/A
9/30/2015	48	-102	N/A	-29	N/A
6/30/2015	85	-54	N/A	-50	N/A
3/31/2015	83	-89	N/A	96	N/A
12/31/2014	41	-117	N/A	111	N/A
9/30/2014	40	-106	N/A	75	N/A
6/30/2014	N/A	-132	N/A	107	N/A
3/31/2014	N/A	-71	N/A	-61	N/A
12/31/2013	N/A	-57	N/A	-49	N/A
9/30/2013	N/A	-42	N/A	-27	N/A
6/30/2013	N/A	-30	N/A	-18	N/A
3/31/2013	N/A	-23	N/A	-13	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: O2T is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: O2T is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: O2T is expected to become profitable in the next 3 years.

Revenue vs Market: O2T's revenue (58% per year) is forecast to grow faster than the German market (3.3% per year).

High Growth Revenue: O2T's revenue (58% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if O2T's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

IVERIC bio Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Forecast to breakeven in 2025

Forecast to breakeven in 2025

No longer forecast to breakeven

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Recent updates

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from NASDAQ Composite Index

IVERIC bio's Common Stock Delisted from NASDAQ

Forecast to breakeven in 2025

Forecast to breakeven in 2025

No longer forecast to breakeven

Forecast to breakeven in 2025

IVERIC bio, Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Iveric Bio Announces the Addition of Pravin U. Dugel to Its Board of Directors

Forecast to breakeven in 2025

Iveric Bio, Inc. Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

IVERIC bio, Inc. has completed a Follow-on Equity Offering in the amount of $300.375 million.

IVERIC bio, Inc. Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

IVERIC bio, Inc. Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

IVERIC bio, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iveric Bio Announces Positive Topline Data from Zimura® Gather2 Phase 3 Clinical Trial in Geographic Atrophy

IVERIC bio, Inc. to Report Q2, 2022 Results on Jul 26, 2022

Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® At American Society of Retina Specialists Meeting

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Value Index

Independent Director recently bought €231k worth of stock

IVERIC bio, Inc. Announces Presentation of Post-Hoc Analysis At Macula Society from Gather1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

IVERIC bio, Inc. Completes Retrospective Review of Choroidal Neovascularization

IVERIC bio, Inc., Annual General Meeting, May 12, 2022

IVERIC bio, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

IVERIC bio, Inc. Announces in GATHER2, the Company's Phase 3 Clinical Trial Evaluating the Safety and Efficacy of Zimura (Avacincaptad Pegol) for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

IVERIC Bio, Inc. Provides Updates on Clinical Trails

IVERIC bio, Inc. Updates on Its Phase 3 Clinical Trails Zimura

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies